36 PEDs cycle progression phase dependent compounds

UNIVERSITY PEDs Cycle Progression: Phase Dependent Compounds Lesson Overview PED deployment for situational drugs Winstrol Halotestin Anadrol Boldenone Sample Contest Prep Cycle design PED Deployment Anabolic Androgenic Steroids Ancillary Compounds Testosterone Based Testosterone Boldenone** Halotestin* Dianabol* Estrogen and Fertility Management Anastrozole* Extremestane* Nolvadex* Clomid* HCG Dihydrotestosterone Based Primobolan Masteron Anavar Proviron Winstrol* Anadrol* Nandrolone (19-Nor) Based Nandrolone Trenbolone* Peptide Hormones Growth Hormone Blood Glucose Metformin Slow and Fast Insulin* Blood Pressure ARBs PPAR y-agonist Telmisartan Fat Loss Agents Clenbuterol* T3/T4* Yohimbine HCl* No asterisk = frequent use allowable; and have been or currently in human clinical use *Phase Dependent Drug to deploy conditionally due to necessity, goal and/or safety risk, have been or currently in human clinical use **Not approved for Human Use, rare situation deployed Winstrol (Stanozolol) Clinical Application Came to market in 1962 Application in osteoporosis, children with growth failure, anti-catabolic during corticosteroid therapy and burns, later used in breast cancer, angioedema (swelling subdermal tissue) Still approved drug, but no longer in usage PED in horse racing Originally dosing 6mg per day Properties Structure: DHT derivative with Pyrazol group in A-ring limiting 3α hydroxysteroid dehydrogenase (3α-HSD) activity in skeletal muscle, improving anabolic property compared to DHT Estrogen Interaction: Not effected by aromatase enzyme, limits any water retention “dry out effect” and increase in androgen to estrogen ratio Progesterone Interaction: Possible slight antagonism 5-alpha reductase interaction: Not subject to 5-alpha reductase, already alpha reduced Glucocorticoid interaction: slight antagonism “dry out effect” SHBG: strong suppressor of SHBG Cardiovascular: 6mg per day for weeks: mean HDL reduction of 33% and 29% increase in LDL Liver:c17aa, liver toxic Studies giving 12mg per day for 27 weeks showed no change in LFTs IM Winstrol still liver toxic Test suppression: 10mg for 14 days enough to suppress natural testosterone for 14 days Tendon ruptures: increases collagen synthesis increase in muscle strength likely effect of increase in tendon damage along with times implemented Winstrol (Stanozolol) Bodybuilding Application Offseason: No application Liver toxic, limited building properties compared to other IM steroids Increased liver toxicity test suppression and lipid alterations compared to Anavar mg for mg Contest Prep: Implemented last 4-6 weeks of contest prep to offset androgen to estrogen ratio allowing for less water retention Increased strength during later stages of dieting Reduction on muscle catabolism Dosing: 25-75mg per day Halotestin (fluoxymesterone) Clinical Application Came to market in 1956 Used in both males and females Osteoporosis, cachectic conditions, treating androgen deficiency, breast cancer Still FDA approved drug but rarely used today Prescribing guidelines of 5-20mg per day Properties Structure: Testosterone derivative w/ fluro group added to carbon and hydroxyl group at carbon 11 enhances anabolic action Estrogen Interaction: Not effected by aromatase enzyme, limits any water retention “dry out effect” and increase in androgen to estrogen ratio 5-alpha reductase interaction: substrate for alpha reductase increasing androgenic action on non skeletal muscle targets Likely the “aggression” known from Halo Cardiovascular: Oral 17aa steroids will alter lipid profiles Liver:c17aa, liver toxic 20mg a day is enough to elevate liver strain Test suppression: 10-30mg highly suppressive to endocrine testosterone Halotestin (fluoxymesterone) Bodybuilding Application Offseason: No application Liver toxic, limited building properties compared to other IM steroids Increased liver toxicity test suppression and lipid alterations Contest Prep: Implemented last weeks of contest prep to offset androgen to estrogen ratio allowing for less water retention Increased strength during later stages of dieting Reduction on muscle catabolism Steroid is expensive and faked, effect can be mimic with Winstrol Dosing: 20-30mg per day Anadrol (Oxymetholone) Clinical Application Came to market in 1960s HIV wasting, COPD Red blood cell deficient Anemia (high increased in RBC production); 1-2mg/kg of body weight to treat anemia Properties Structure: unique DHT derivative; 2-hydroxymethylene group inhibits 3-hydroxy steroid dehydrogenase Closer behavior to that of nandrolone than a DHT Estrogen Interaction: Highly estrogenic with potential to bind the estrogen receptor but not subject to the aromatase enzyme, high amount of water retention 5-alpha reductase interaction: Not a substrate for alpha reductase however the 2-hydroxymethylene group can be removed, reducing anadrol to mestanolone, a potent androgen Cardiovascular: 50mg or 100mg daily given to 31 elderly men for 12 weeks caused a 19 and 23 point drop in HDL, respectively Liver:c17aa, liver toxic 50mg or 100mg daily given to 31 elderly men for 12 weeks increase LFTs significantly only in the 100mg group 50mg daily of one year increased GGT 17% and patient incurring a liver tumor Well known for decreasing appetite Anadrol (Oxymetholone) *Overall Not Recommended Bodybuilding Application Offseason: Limited application Liver toxic, high RBC promotion, high water retention, high blood pressure Not ideal for long term safe usage model Strength and mass increase, however, may compromise appetite and defeat that point of offseason and pushing food up Some use as a “plateau breakthrough”, but I see this is not needed when we have injectables like Testosterone and Nandrolone Dosing: 50mg 4-6 weeks Contest Prep: Poor application in contest prep Anadrol ”loading” has been done as a peaking strategy, however the fullness from water retention is typically seen extracellular as well Dianabol (methandienone) Clinical Application 1958 released to market Post menopausal osteoporosis, pituitary deficient dwarfism 1980s withdrawn from market 5mg per day clinical dosing Properties Structure: testosterone derivative; double bond added b/w carbon and reduces androgenicity compared to testosterone Estrogen Interaction: subject to aromatase enzyme into 17alphamethylestradiol, high water retention with this compound 5-alpha reductase interaction: limited interaction with 5-alpha reductase Cardiovascular: being that it is c17aa oral it will alter lipid levels significantly Liver:c17aa, liver toxic Dosages over 10mg per day have shown liver stress altered Testosterone suppression: 15mg per day for weeks caused a 59% reduction in endocrine test levels Dianabol (Methandienone) *Overall Not Recommended Bodybuilding Application Offseason: Poor application Liver toxic,, high water retention, high blood pressure Not ideal for long term safe usage model Most gains will be water retention, subject to appetite decrease like Anadrol I see no place for this compound Contest Prep: No application here Equipose (boldenone) Clinical Application Patented in 1940s Brief history of human usage in 60s, clinical trials for osteoporosis (not used as “better” steroids existed) 1970s brought to veterinary market for horses (lean bodyweight, appetite) owned by Pfizer Not human approved Properties Structure: testosterone derivative; double bond b/w and carbon, reducing estrogenicity Identical structure to Dianabol, different behavior Anabolic, low androgenic Estrogen Interaction: Subject to aromatase enzyme but far less than testosterone 5-alpha reductase interaction: limited interaction with 5-alpha reductase Will convert to Dihydroboldenone but limited Cardiovascular: No research in humans but subject to same effects of HDL lowering as other IM steroids Liver: Not c-17 aa and limited hepatotoxic, but also limited human data Erythrocytosis: all steroids increase EPO, potentially more renal toxic, increased blood pressure Equipose (boldenone) *Overall Not Recommended Bodybuilding Application Offseason: Poor application Boldenone brings more anabolism to a cycle with some estrogen, we have better drugs to this (testosterone + primobolan or masteron) Boldenone is potentially more renal toxic than comparable compounds as well Not ideal for long term safe usage model Contest Prep: No application here for same reasons above Sample Cycle Progression Contest Prep intermediate/advanced 16 weeks out Test cypionate 300mg/wk Primobolan 400mg /wk GH 2IU pre workout and pre bedtime 12 weeks out Test cypionate 300mg/wk Primobolan 400mg/wk Masteron 400mg/wk GH 2IU pre workout and pre bedtime weeks out Test cypionate 300mg/wk Trenbolone 200mg/wk Masteron 400mg/wk GH 2IU pre workout and pre bedtime weeks out Test cypionate 300mg/wk Trenbolone 200mg/wk Masteron 200mg/wk Winstrol 50mg/day GH 2IU pre workout and pre bedtime weeks out Test cypionate 300mg/wk *drop test weeks out if needed for water retention Trenbolone 200mg/wk Masteron 200mg/wk Winistrol 50mg/day Halotestin 20mg/day GH 2IU pre workout and pre bedtime *drop GH weeks out Summary Testosterone is our established base growth anchor A DHT derivative like Proviron, Anavar, Primobolan and/or Masteron are secondary compounds to deploy Our next deployed drug will be a nandrolone derivative Nandrolone for offseason usage and Trenbolone reserved in contest prep Growth hormone and insulin will be implemented into the intermediate level to maximize synergies Phase dependent steroids will be implemented such as Winstrol and Halotestin during contest prep I see no place for need of Dianabol, Anadrol, or boldenone is safer use PED protocols Compounds to mention: DHB, Superdrol, Turinabol, Trestalone, SARMS By this point further advancing of cycle likely will need aromatase inhibitors and Selective Estrogen Receptor Modulators Combating effects of estrogen and prolactin will be next References Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Zamel N, Brooks D, Jardim JR The influence of months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients Chest 1998 Jul;114(1):19-28 doi: 10.1378/chest.114.1.19 PMID: 9674442 Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN Contrasting effects of testosterone and stanozolol on serum lipoprotein levels JAMA 1989 Feb 24;261(8):1165-8 PMID: 2915439 Small M, Beastall GH, Semple CG, Cowan RA, Forbes CD Alteration of hormone levels in normal males given the anabolic steroid stanozolol Clin Endocrinol (Oxf) 1984 Jul;21(1):4955 doi: 10.1111/j.1365-2265.1984.tb00135.x PMID: 6430603 Schroeder ET, Singh A, Bhasin S, Storer TW, Azen C, Davidson T, Martinez C, Sinha-Hikim I, Jaque SV, Terk M, Sattler FR Effects of an oral androgen on muscle and metabolism in older, community-dwelling men Am J Physiol Endocrinol Metab 2003 Jan;284(1):E120-8 doi: 10.1152/ajpendo.00363.2002 Epub 2002 Sep 24 PMID: 12388137 Shabir N et al Effect of Nandrolone Decanoate, Boldenone Undecylenate on Renal Status of Rabbits (Oryctolagus cuniculus Global Veterinaria 14 (3): 432-438, 2015 DOI: 10.5829/idosi.gv.2015.14.03.92201 Kantarci UH, Punduk Z, Senarslan O, Dirik A Evaluation of anabolic steroid induced renal damage with sonography in bodybuilders J Sports Med Phys Fitness 2018 Nov;58(11):16811687 doi: 10.23736/S0022-4707.17.06763-9 Epub 2017 Nov 17 PMID: 29148625 Books: Llewellyn W Anabolics Jupiter, FL: Molecular Nutrition LLC; 2017 Bond P Book on Steroids: A complete evidence based reference PeterBond.org; 2020  ... synergies Phase dependent steroids will be implemented such as Winstrol and Halotestin during contest prep I see no place for need of Dianabol, Anadrol, or boldenone is safer use PED protocols Compounds. .. HCl* No asterisk = frequent use allowable; and have been or currently in human clinical use *Phase Dependent Drug to deploy conditionally due to necessity, goal and/or safety risk, have been or... more anabolism to a cycle with some estrogen, we have better drugs to this (testosterone + primobolan or masteron) Boldenone is potentially more renal toxic than comparable compounds as well Not